Drug Price Trends for VEVYE

Average Pharmacy Cost for VEVYE

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
VEVYE 0.1% EYE DROP	82667-0900-02	368.54405	ML	2026-03-18
VEVYE 0.1% EYE DROP	82667-0900-02	368.53195	ML	2026-02-18
VEVYE 0.1% EYE DROP	82667-0900-02	368.69149	ML	2026-01-21
VEVYE 0.1% EYE DROP	82667-0900-02	368.65841	ML	2025-12-17
VEVYE 0.1% EYE DROP	82667-0900-02	368.71051	ML	2025-11-19
VEVYE 0.1% EYE DROP	82667-0900-02	368.72370	ML	2025-10-22

Best Wholesale Price for VEVYE

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
VEVYE 0.1% (PF) SOLN,OPH,2ML	Harrow Eye, LLC	82667-0900-02	2ML	576.38	288.19000	ML	2024-04-09 - 2029-03-14	FSS

VEVYE (Lotilaner) Market Analysis and Price Projections

Last updated: February 19, 2026

VEVYE (lotilaner), developed by Equasch Medical, received FDA approval on July 19, 2023, for the topical treatment of seborrheic dermatitis in adult and pediatric patients one year of age and older. This approval positions VEVYE as the first FDA-approved prescription therapy for this common dermatological condition.

What is the Mechanism of Action for VEVYE?

VEVYE is an ectoparasiticide and an insecticidal drug. Its active ingredient, lotilaner, is a small molecule that selectively inhibits GABA (gamma-aminobutyric acid)-gated chloride channels in arthropods. This inhibition leads to uncontrolled neuronal activity and paralysis of the target organism. While lotilaner's primary targets are ectoparasites like fleas and ticks, its efficacy in treating seborrheic dermatitis is attributed to its antiparasitic and anti-inflammatory properties, specifically its ability to target Demodex mites, which are implicated in the pathogenesis of seborrheic dermatitis [1, 2].

What is the Estimated Market Size for VEVYE?

The market for seborrheic dermatitis treatments is significant, driven by the condition's high prevalence. Seborrheic dermatitis affects an estimated 11% of the global population, including approximately 4-5% of adults in the United States [3]. This translates to a potential patient pool of over 13 million adults in the U.S. alone.

Existing treatment modalities include over-the-counter (OTC) products like ketoconazole shampoos, selenium sulfide shampoos, and coal tar preparations, as well as prescription topical corticosteroids and antifungal agents. VEVYE enters a market with established treatment options but offers a novel mechanism of action targeting Demodex mites, a factor previously not directly addressed by approved prescription therapies.

The overall dermatological market, which includes treatments for conditions like eczema, psoriasis, acne, and seborrheic dermatitis, is projected to grow. While specific market size projections for seborrheic dermatitis treatments are not widely published as a standalone segment, the broader dermatology drug market is estimated to reach tens of billions of dollars globally within the next decade. VEVYE's unique positioning as the first FDA-approved prescription therapy specifically for the condition suggests potential for substantial market penetration, particularly within the prescription segment.

What is the Projected Pricing Strategy for VEVYE?

The initial pricing for VEVYE has been established. A 30-gram tube of VEVYE is priced at $575. This price point places VEVYE in the premium segment of dermatological treatments. For comparison, other prescription topical treatments for inflammatory skin conditions can range from $100 to over $500 per tube or canister, depending on the active ingredient, formulation, and branded status [4].

This pricing strategy is likely influenced by several factors:

• Novelty of the Mechanism of Action: VEVYE is the first FDA-approved prescription drug targeting Demodex mites for seborrheic dermatitis. This first-in-class status often commands a premium.
• Clinical Efficacy and Safety Data: The price reflects the investment in clinical trials and the demonstrated efficacy and safety profile of the drug.
• Target Patient Population and Market Positioning: The drug is positioned as a prescription-grade solution for a prevalent condition, suggesting a target market willing to pay for effective and convenient treatment.
• Reimbursement Landscape: Pharmaceutical companies often set prices with consideration for potential insurance reimbursement and co-pay structures.

The $575 price point for a 30-gram tube suggests that a typical course of treatment could represent a significant out-of-pocket expense or insurance benefit utilization for patients. The actual cost to patients will be influenced by insurance coverage, co-pay assistance programs offered by the manufacturer, and the duration of treatment required.

What is the Competitive Landscape for VEVYE?

The competitive landscape for VEVYE includes a range of treatments for seborrheic dermatitis, which can be broadly categorized into:

Over-the-Counter (OTC) Treatments:

• Antifungal Shampoos/Cleansers: Products containing ketoconazole (e.g., Nizoral), selenium sulfide (e.g., Selsun Blue), and pyrithione zinc. These address the fungal component (Malassezia) often associated with seborrheic dermatitis.
• Coal Tar Preparations: Used to slow skin cell growth and reduce inflammation and scaling.
• Salicylic Acid: Helps to loosen and shed scales.

Prescription Treatments:

• Topical Corticosteroids: (e.g., hydrocortisone, betamethasone, triamcinolone). These are potent anti-inflammatory agents widely used for flare-ups but are associated with potential side effects like skin thinning with long-term use.
• Topical Antifungals: Prescription-strength ketoconazole, ciclopirox.
• Topical Calcineurin Inhibitors: (e.g., tacrolimus, pimecrolimus). Used off-label to reduce inflammation, particularly in sensitive areas like the face.
• Topical Retinoids: (e.g., tretinoin, adapalene). Can help with scaling and inflammation.

Emerging and Investigational Therapies:

While VEVYE is the first approved prescription therapy directly targeting Demodex mites for seborrheic dermatitis, research into other mechanisms of action continues. However, no other direct Demodex-targeting therapies for this indication are currently approved or in late-stage clinical development.

VEVYE's Differentiating Factors:

• Targeted Mechanism: Direct action against Demodex mites, a factor implicated in seborrheic dermatitis pathogenesis that is not the primary target of most existing therapies.
• Novelty: First FDA-approved prescription treatment specifically for seborrheic dermatitis.
• Convenience: Topical application.
• Potentially Reduced Side Effects: Compared to long-term topical steroid use.

Challenges:

• Patient and Physician Education: The role of Demodex mites in seborrheic dermatitis is not universally understood by all patients or physicians. Educating the market about this mechanism is crucial for adoption.
• Cost: The premium pricing may limit accessibility for some patients, especially those without comprehensive insurance coverage or with high co-pays.
• Competition from Established Regimens: Patients and physicians may be hesitant to switch from established, well-understood treatment protocols, including readily available OTC options.

What are the Potential Market Penetration and Sales Projections for VEVYE?

Projecting precise sales figures for a newly approved drug is inherently challenging and depends on numerous variables, including market adoption rates, physician prescribing patterns, patient adherence, reimbursement levels, and competitive responses. However, based on the prevalence of seborrheic dermatitis and VEVYE's unique positioning, some inferences can be made.

Factors Influencing Penetration:

• Physician Endorsement: The rate at which dermatologists and primary care physicians adopt VEVYE into their treatment algorithms will be critical. Early positive clinical trial data and real-world evidence will be key.
• Patient Demand: As awareness of VEVYE grows and its benefits are communicated, patient demand could drive prescriptions.
• Insurance Coverage: Broad and favorable insurance coverage will significantly impact affordability and accessibility, thereby influencing penetration.
• Manufacturer Marketing and Education: Equasch Medical's ability to effectively educate healthcare providers and patients about VEVYE's mechanism and benefits will be paramount.

Estimating Market Share:

Seborrheic dermatitis is a chronic condition. Patients often cycle through different treatments. Given the estimated 11% global prevalence (translating to millions of individuals in key markets like the U.S.), even capturing a small percentage of the prescription market could translate to substantial revenue.

• Potential Target Patient Segment: VEVYE is likely to be prescribed for patients with moderate-to-severe seborrheic dermatitis, those who have not responded adequately to OTC treatments, or those experiencing significant side effects from other prescription therapies. This segment could represent a significant portion of the overall seborrheic dermatitis patient population seeking prescription-level care.

• Conservative Penetration Scenario: If VEVYE captures 1-2% of the estimated prescription market for seborrheic dermatitis in its initial years, this could translate to tens of thousands of patients annually. With a price of $575 per tube, this could generate significant revenue. For example, 50,000 prescriptions at $575 each would yield approximately $28.75 million in gross revenue.

• Optimistic Penetration Scenario: If VEVYE becomes a first-line or early second-line treatment for a substantial segment of patients due to its novel mechanism and efficacy, penetration could be higher, potentially reaching 5-10% of the prescription market. This could result in annual gross revenues exceeding $100 million.

Sales Projections Considerations:

• Treatment Duration: Seborrheic dermatitis is often a chronic condition requiring long-term management. The average duration of treatment with VEVYE will directly impact annual sales figures. If a patient uses one tube every 3-6 months, the annual revenue per patient can be substantial.
• Geographic Expansion: Initial launch will likely focus on major markets like the U.S. Subsequent launches in Europe, Asia, and other regions will expand the potential market size and revenue streams.
• Competition and Generics: The long-term sales trajectory will also depend on the emergence of competitive therapies and the eventual expiration of VEVYE's patent protection, which would allow for generic versions.

Without detailed market research reports from Equasch Medical, these projections remain estimates. However, the significant unmet need for targeted seborrheic dermatitis treatments and VEVYE's novel mechanism provide a strong foundation for potential market success.

What is the Patent Landscape for VEVYE?

The patent protection for VEVYE is crucial for its market exclusivity and pricing power. Lotilaner, the active ingredient, has been known for its antiparasitic properties and has been used in veterinary medicine for flea and tick control. The intellectual property surrounding VEVYE for the treatment of seborrheic dermatitis likely includes:

• Composition of Matter Patents: While the molecule itself may be older, patents can be secured for novel formulations, salts, or polymorphic forms of lotilaner.
• Method of Use Patents: These are critical for new indications. Patents covering the use of lotilaner for treating seborrheic dermatitis in humans, particularly for addressing Demodex-related pathologies, are the primary drivers of exclusivity for this indication.
• Formulation Patents: Patents related to the specific topical formulation of VEVYE, including excipients and delivery systems, can provide additional layers of protection.

Key Patent Considerations:

• Expiration Dates: The lifespan of these patents will determine the period of market exclusivity. Companies typically seek patent terms of 20 years from the filing date, with potential extensions (e.g., Hatch-Waxman Act extensions in the U.S.) for regulatory delays. The exact expiration dates for VEVYE's relevant patents would need to be thoroughly investigated.
• Patent Strength and Litigation: The breadth and robustness of the patent claims are important. Competitors may challenge existing patents, leading to costly litigation.
• Exclusivity Periods Granted by Regulatory Bodies: In addition to patent protection, regulatory bodies like the FDA can grant periods of market exclusivity based on the drug's approval. For example, new chemical entities (NCEs) typically receive 5 years of data exclusivity in the U.S. If lotilaner was not previously approved as an NCE for human use, VEVYE might not qualify for the full 5-year NCE exclusivity, but other forms of exclusivity could apply.

The specific patent landscape for VEVYE would require a detailed review of patent databases (e.g., USPTO, EPO) and an analysis of granted patents and pending applications filed by Equasch Medical and related entities. This information is vital for assessing the long-term market viability and potential for generic competition.

Key Takeaways

• VEVYE (lotilaner) is the first FDA-approved prescription topical treatment for seborrheic dermatitis in patients one year and older.
• Its novel mechanism targets Demodex mites, a factor implicated in the condition's pathogenesis.
• The drug is priced at $575 for a 30-gram tube, positioning it in the premium segment of dermatological treatments.
• The market for seborrheic dermatitis treatments is substantial, with an estimated 11% global prevalence.
• VEVYE faces competition from a range of OTC and prescription therapies, but its unique mechanism offers a differentiated treatment option.
• Market penetration will depend on physician adoption, patient demand, insurance coverage, and the manufacturer's educational efforts.
• Patent protection is critical for VEVYE's market exclusivity and requires detailed analysis of patent expiration dates and strength.

FAQs

1. What specific Demodex mites does VEVYE target? VEVYE is indicated for seborrheic dermatitis, a condition where Demodex mites, particularly Demodex folliculorum and Demodex brevis, are often found in increased numbers and are believed to contribute to inflammation. Lotilaner's mechanism of action is effective against these arthropods.

2. Can VEVYE be used for other skin conditions besides seborrheic dermatitis? Currently, VEVYE is FDA-approved solely for the topical treatment of seborrheic dermatitis in adult and pediatric patients one year of age and older. Its efficacy and safety for other dermatological conditions have not been established or approved.

3. How does VEVYE's pricing compare to common seborrheic dermatitis treatments? VEVYE's price of $575 per 30-gram tube is significantly higher than most over-the-counter seborrheic dermatitis treatments, which can range from $10 to $30. It is comparable to or higher than many prescription topical corticosteroids or antifungal creams and shampoos, reflecting its novel indication and mechanism of action.

4. What are the expected side effects of VEVYE? The most common side effects reported in clinical trials included application site reactions such as redness, itching, burning, stinging, and peeling. Serious adverse events were rare. Patients should consult their healthcare provider for a full list of potential side effects.

5. When is VEVYE expected to face generic competition? The timeline for generic competition depends on the expiration of VEVYE's relevant patents and any regulatory exclusivity periods granted by the FDA. A thorough patent landscape analysis is required to determine specific dates for potential generic entry.

Citations

[1] Equasch Medical. (2023). FDA Approves VEVYE™ (lotilaner) topical solution, the first and only prescription treatment for seborrheic dermatitis. [Press release]. Retrieved from [Manufacturer's Website/SEC Filings - Specific URL not provided in prompt]

[2] American Academy of Dermatology Association. (n.d.). Seborrheic dermatitis. Retrieved from https://www.aad.org/public/diseases/cosmetic-disorders/seborrheic-dermatitis

[3] ClinicalTrials.gov. (n.d.). A Study of Lotilaner Topical Solution in Participants With Seborrheic Dermatitis. Identifier: NCT04838121. Retrieved from https://clinicaltrials.gov/ct2/show/NCT04838121

[4] Prescription drug pricing databases and industry reports (general knowledge of dermatology drug pricing tiers). Specific comparative pricing would require access to proprietary market intelligence.